Merck & Co Option Alert: Oct 17 $85 Puts at the Ask: 1850 vs 1821 OI

Merck & Co Option Alert: Oct 17 $85 Puts at the Ask: 1850 @ $2.81 vs 1821 OI; Ref=$87.18

Merck & Co Option Alert: Sep 19 $85 Calls Sweep (85) near the Bid: 2209 vs 21153 OI

Merck & Co Option Alert: Sep 19 $85 Calls Sweep (85) near the Bid: 2209 @ $3.601 vs 21153 OI; Ref=$86.995

Merck & Co

MERCK & CO. INC.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.

Merck & Co Inc

Marker Therapeutics Inc

MARKY CORP by MARKY CORP.

Opinion

Press Releases

Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas

REPAY Appoints New Chief Financial Officer

KEYTRUDA® (pembrolizumab) plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free and Overall Survival and Pathologic Complete Response Rate for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery

Health Canada Approves KEYTRUDA® for Patients with Resectable Locally Advanced Head & Neck Squamous Cell Carcinoma Tumours that are PD-L1 (CPS) Positive as Neoadjuvant Treatment, Continued as Adjuvant Treatment Combined With Radiotherapy With or Without Cisplatin Then as Monotherapy

Ifinatamab Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Pretreated Extensive-Stage Small Cell Lung Cancer

The Next Wave of Cancer Innovation: How Breakthrough Therapies Are Redefining Treatment Paradigms

Vets and Pet-Owners See Gaps in Flea and Tick Prevention, Highlighting Need for Year-Round Care, New Merck Animal Health Global Survey Finds

Merck Demonstrates Ongoing Commitment to Advancing Cardiovascular Disease Management and Patient Care with New Data at the European Society of Cardiology Congress 2025

HERTHENA-Breast04 Phase 3 Trial of Patritumab Deruxtecan Initiated in Patients with Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer Previously Treated with Endocrine Therapy

Merck to Participate in the 2025 Wells Fargo Healthcare Conference

BNTX

CNDT

GEHC

IART

INSM

NVDA

PPCB

RPAY

SNGX

TYO:4568

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Ligand Pharmaceuticals Incorporated - Common Stock

Ligand Pharmaceuticals

Eli Lilly

Novo Nordisk

Novartis

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Perrigo

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Verona Pharma plc - American Depositary Shares

Verona Pharma

Viatris

Zoetis

Wells Fargo

Morgan Stanley

Citigroup

Cantor Fitzgerald

Guggenheim

Screenshot 2025-07-10 at 8.34.03 PM

Biotech

News

KERX

When it comes to unmet needs in the nephrology space, acute kidney injury remains a significant concern.

SeaStar Medical&#39;s QUELIMMUNE Wins Prestigious Award From The National Kidney Foundation, Former Winners Include Names Like Janssen, Merck and Otsuka

Screenshot 2025-05-21 at 5.43.26 PM

SPACE

Emerging Markets

ASTI

Space Exploration Will Continue Despite NASA Budget Cuts – How Will CIGS-Maker Ascent Solar (ASTI) Be Impacted?

Screenshot 2024-09-30 at 9.13.36 PM

General

TNXP

VRTX

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-09-30 at 5.38.54 PM

Movers & Shakers

COSM

Nestle Sponsored representing Registered Shares Series B

NSRGY

VTRS

How Cosmos Health&#39;s Acquisition Of Almost 100-Year-Old Company, Adding To Capabilities Like Contract Manufacturing, Could Generate Over $10 Million In Annual Gross Profit

Date	Put/Call	Strike Price	Exp Date	DTE	Trade Vol	Day Vol	Vol / OI	OI	Trade Type	Sentiment
11:48 AMAug 22, 2025	PUT	$85.00	Oct 17, 2025	48	1936	1850	106	1821	TRADE	BEARISH
10:50 AMAug 22, 2025	CALL	$85.00	Sep 19, 2025	20	2602	2209	12	21153	SWEEP	BEARISH

Comments

Merck & Co

Unusual Options Activity for

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL